EKO International Corp. (EKNL) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.16: the stock has moved about 16% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEKO International Corp. (EKNL) trades at $0.0002. EKO International Corp. operates through a joint venture, NeuroVasc Clinical Inc., focusing on the distribution and management of clinics using FREMSTM equipment for peripheral neuropathy treatment in Canada. Sector: Industrials.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for EKNL: EKNL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
EKO International Corp. (EKNL) Industrial Operations Profile
EKO International Corp. is a Canada-based company operating in the industrials sector, specializing in the distribution and clinic management of FREMSTM equipment for peripheral neuropathy treatment through its joint venture, NeuroVasc Clinical Inc., primarily serving the Canadian market.
What Is the Investment Thesis for EKNL?
Investing in EKO International Corp. presents a speculative opportunity, given its focus on a niche market within the healthcare sector, specifically peripheral neuropathy treatment using FREMSTM technology. Key value drivers include the potential expansion of NeuroVasc Clinical Inc.'s clinic network and increased adoption of FREMSTM equipment. However, the company's OTC listing and associated risks, including limited financial disclosure and potential shell risk, warrant careful consideration. The success of the investment hinges on the company's ability to effectively market and distribute its technology and manage its clinic operations. The company's beta of 1.16 suggests a higher volatility compared to the market.
Based on FMP financials and quantitative analysis
EKNL Key Highlights
EKO International Corp. operates through a joint venture interest in NeuroVasc Clinical Inc., focusing on peripheral neuropathy treatment.
- The company distributes frequency rhythmic electrical modulation system (FREMSTM) equipment.
- EKO International Corp. sets up and manages clinics that utilize FREMSTM equipment.
- The company is based in Burlington, Canada, focusing its operations within the Canadian market.
- EKO International Corp. has a market capitalization of $0.00B, indicating its small size.
Who Are EKNL's Competitors?
EKNL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ASNCF A-Sonic Aerospace Limited | $0.24 | 0.00% | $24.4M | — |
| TUSK Mammoth Energy Services, Inc. | $2.84 | +1.43% | $137M | 38 5-pillar |
| RCMT RCM Technologies, Inc. | $41.59 | -1.00% | $295M | 92 5-pillar |
| FIP FTAI Infrastructure Inc. | $2.71 | +0.93% | $320M | — |
| NNBR NN, Inc. | $4.24 | -5.99% | $350M | — |
| TRC Tejon Ranch Co. | $16.18 | -1.22% | $442M | 50 5-pillar |
| MATW Matthews International Corporation | $19.33 | +0.21% | $602M | 36 5-pillar |
| CRESY Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria | $11.88 | +4.76% | $736M | 49 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EKNL's Key Strengths?
Specialized focus on peripheral neuropathy treatment.
- Proprietary FREMSTM technology.
- Clinic network provides direct access to patients.
- Joint venture with NeuroVasc Clinical Inc.
What Are EKNL's Weaknesses?
Small market capitalization.
- Limited geographic presence (Canada).
- Reliance on a single technology (FREMSTM).
- OTC listing with associated risks.
What Are the Key Risks for EKNL?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial disclosure makes it difficult to assess the company's financial health.
- Competition from established medical device companies in the neuropathy treatment market.
- Regulatory hurdles in expanding operations to new geographic markets.
- The company's OTC listing and associated risks, including limited liquidity and potential shell risk.
- Technological obsolescence of FREMSTM equipment.
What Are EKNL's Competitive Advantages?
- Proprietary Technology: FREMSTM technology may offer a unique approach to peripheral neuropathy treatment.
- Clinic Network: The managed clinic network provides a direct channel for delivering treatment services.
- Joint Venture: The joint venture with NeuroVasc Clinical Inc. provides access to specialized expertise and resources.
What Does EKNL Do?
EKO International Corp., based in Burlington, Canada, operates primarily through its joint venture interest in NeuroVasc Clinical Inc. The company focuses on the promotion and distribution of frequency rhythmic electrical modulation system (FREMSTM) equipment. This equipment is specifically used in the treatment of peripheral neuropathy. In addition to distribution, EKO International Corp., via NeuroVasc Clinical Inc., is involved in setting up and managing clinics that provide treatment to patients using the FREMSTM technology. The company's business model centers around providing a comprehensive solution for peripheral neuropathy treatment, combining equipment distribution with clinical service delivery. The company's operations are currently concentrated within Canada, and the company's focus remains on expanding the reach and effectiveness of FREMSTM technology in treating peripheral neuropathy.
What Products and Services Does EKNL Offer?
- Promotes and distributes frequency rhythmic electrical modulation system (FREMSTM) equipment.
- Focuses on equipment used in the treatment of peripheral neuropathy.
- Sets up and manages clinics to treat patients using FREMSTM equipment.
- Operates through a joint venture interest in NeuroVasc Clinical Inc.
- Provides a comprehensive solution for peripheral neuropathy treatment combining equipment distribution with clinical service delivery.
How Does EKNL Make Money?
- Equipment Sales: Generates revenue through the sale of FREMSTM equipment to clinics and healthcare providers.
- Clinic Management Fees: Earns fees for setting up and managing clinics that utilize FREMSTM equipment.
- Treatment Services: Revenue is generated from providing treatment services to patients at the managed clinics.
What Industry Does EKNL Operate In?
EKO International Corp. operates within the industrials sector, specifically as a conglomerate through its healthcare-related joint venture. The market for peripheral neuropathy treatment is growing, driven by an aging population and increasing prevalence of diabetes, a major risk factor for the condition. The competitive landscape includes medical device companies and specialized clinics offering various treatment modalities. EKO International Corp.'s focus on FREMSTM technology positions it within a niche segment of this market, requiring effective marketing and clinical validation to compete effectively.
Who Are EKNL's Key Customers?
- Clinics specializing in neuropathy treatment.
- Healthcare providers seeking advanced treatment options.
- Patients suffering from peripheral neuropathy.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
EKO International Corp. operates in the Conglomerates industry within the Industrials sector. It is headquartered in Burlington, CA. The company is led by CEO Rocky DiBenedetto. EKNL has traded publicly since 1997.
Key Financial Metrics
Return on equity for EKO International Corp. stands at 386.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
EKO International Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
EKNL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
EKNL Latest News
No recent news available for EKNL.
EKNL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EKNL.
Price Targets
Wall Street price target analysis for EKNL.
EKNL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EKNL; grades run from A+ (80-100) to F (below 30).
Leadership: Rocky DiBenedetto
CEO
Without additional details, it is difficult to provide a comprehensive overview of his career history, education, or previous roles. Further research would be needed to ascertain his relevant experience and qualifications.
Track Record: Information on Rocky DiBenedetto's track record is not available in the provided data. Without specific achievements, strategic decisions, or company milestones under his leadership, it is impossible to assess his performance as CEO. Further research would be needed to evaluate his contributions to EKO International Corp.
EKNL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EKO International Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure, and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to stocks listed on senior exchanges.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The unknown disclosure status makes it difficult to assess the company's financial health.
- Potential Shell Risk: The detected shell risk indicates a higher potential for fraudulent activity or manipulation.
- Limited Liquidity: OTC stocks often have low trading volume, making it difficult to buy or sell shares.
- Lack of Regulatory Oversight: OTC markets have less stringent regulatory requirements than major exchanges.
- Verify the company's legal status and registration.
- Investigate the background and experience of the management team.
- Attempt to obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Joint Venture: The joint venture with NeuroVasc Clinical Inc. suggests some level of operational activity.
- Focus on Healthcare: The company's focus on peripheral neuropathy treatment aligns with a growing healthcare need.
- Operational Activity: The company sets up and manages clinics, indicating some business operations.
EKNL Industrials Stock FAQ
What are the main risks for EKNL?
The main risks for EKO International Corp. (EKNL) include its OTC listing, which is associated with limited liquidity, potential shell risk, and a lack of regulatory oversight.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on EKO International Corp.
- OTC stocks are inherently riskier than exchange-listed stocks.
- Financial data is limited.